379 related articles for article (PubMed ID: 3498818)
1. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
Kindt MV; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.
Sonsalla PK; Youngster SK; Kindt MV; Heikkila RE
J Pharmacol Exp Ther; 1987 Sep; 242(3):850-7. PubMed ID: 2888874
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
Finnegan KT; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
[TBL] [Abstract][Full Text] [Related]
4. Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice.
Abdel-Wahab MH
J Biochem Mol Toxicol; 2005; 19(1):32-41. PubMed ID: 15736157
[TBL] [Abstract][Full Text] [Related]
5. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies.
Manaye KF; Sonsalla PK; Barnett G; Heikkila RE; Woodward DJ; Smith WK; German DC
Brain Res; 1989 Jul; 491(2):307-15. PubMed ID: 2765888
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.
Youngster SK; Nicklas WJ; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565
[TBL] [Abstract][Full Text] [Related]
7. Attenuation by dopamine uptake blockers of the inhibitory effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and some of its analogs on NADH-linked metabolism in mouse neostriatal slices.
Ofori S; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1989 Oct; 251(1):258-66. PubMed ID: 2571719
[TBL] [Abstract][Full Text] [Related]
8. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
Riachi NJ; Harik SI; Kalaria RN; Sayre LM
J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
[TBL] [Abstract][Full Text] [Related]
10. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
[TBL] [Abstract][Full Text] [Related]
11. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.
Vyas I; Heikkila RE; Nicklas WJ
J Neurochem; 1986 May; 46(5):1501-7. PubMed ID: 3485701
[TBL] [Abstract][Full Text] [Related]
12. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
[TBL] [Abstract][Full Text] [Related]
13. MPTP, MPP+ and mitochondrial function.
Nicklas WJ; Youngster SK; Kindt MV; Heikkila RE
Life Sci; 1987 Feb; 40(8):721-9. PubMed ID: 3100899
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
[TBL] [Abstract][Full Text] [Related]
16. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.
Rollema H; Skolnik M; D'Engelbronner J; Igarashi K; Usuki E; Castagnoli N
J Pharmacol Exp Ther; 1994 Jan; 268(1):380-7. PubMed ID: 8301579
[TBL] [Abstract][Full Text] [Related]
17. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
18. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
19. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Giovanni A; Sonsalla PK; Heikkila RE
J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
[TBL] [Abstract][Full Text] [Related]
20. Does paraquat (PQ) mimic MPP+ toxicity?
Woolley DE; Gietzen DW; Gee SJ; Magdalou J; Hammock BD
Proc West Pharmacol Soc; 1989; 32():191-3. PubMed ID: 2789384
[No Abstract] [Full Text] [Related]
[Next] [New Search]
